Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis
Margitta Worm(Charité - Universitätsmedizin Berlin), Marius Ardeleanu(Regeneron (United States)), Stefan Beissert(University Hospital Carl Gustav Carus), Robert Bissonnette(Innovaderm (Canada)), Manoj Rajadhyaksha(Alexion Pharmaceuticals (United States)), Makoto Kawashima(Tokyo Women's Medical University), Thomas Hultsch(Sanofi (United States)), Laurent Eckert(Sanofi (France)), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Bolanle Akinlade(Regeneron (United States)), Neil M.H. Graham(UK Dementia Research Institute), Lisa A. Beck(University of Rochester Medicine), Neil Stahl(Arthritis and Rheumatism Associates), George D. Yancopoulos(Regeneron (United States)), Diamant Thaçi(University of Lübeck), Catherine Smith(City College of San Francisco), Carlos Ferrándiz(Universitat Autònoma de Barcelona), Heribert Staudinger(Sanofi (United States)), Zhen Chen(Chongqing Medical University), Gianluca Pirozzi(Sanofi (United States)), Kuo‐Chen Chan(Regeneron (United States)), John D. Davis(Providence College), Abhijit Gadkari(Regeneron (United States)), Eric L. Simpson(Oregon Health & Science University)
Cited by 211
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans
|Science|2009|2.5k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k